Astera Labs (NASDAQ:ALAB) Shares Up 13.7% – Still a Buy?

Astera Labs, Inc. (NASDAQ:ALAB)’s stock price traded up 13.7% on Monday. The company traded as high as $220.08 and last traded at $216.87. 7,049,015 shares were traded during trading, an increase of 37% from the average daily volume of 5,161,966 shares. The stock had previously closed at $190.71.

Astera Labs News Summary

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: A bullish analyst note highlighted rising revenue per accelerator as customers shift toward higher-value Scorpio switches. Astera Labs reported third-quarter revenue of about $585 million and guided to roughly $740 million at the midpoint for the fourth quarter, supporting the growth outlook. Article: Astera Labs Is Increasing Their Revenue Per Accelerator
• Positive Sentiment: ALAB rallied alongside a broader technology-stock surge on Nov. 9, providing a sector-driven boost after a steep recent decline. Article: Astera Labs rallies on tech stock surge
• Neutral Sentiment: Astera Labs will participate in the BMO Technology and Innovation Leaders Conference on Nov. 12. The event could provide an opportunity for investor updates, but no new financial guidance was announced. Article: Astera Labs Announces Upcoming Financial Conference Participation
• Neutral Sentiment: A short-interest report says the Nov. 10 balance was zero shares and days to cover were zero, despite describing short interest as having increased. The figures therefore do not indicate meaningful short positioning.
• Negative Sentiment: ETFs were net sellers of about $80.2 million in ALAB on Nov. 6, signaling institutional selling pressure. Article: ETFs Are Net Sellers of Astera Labs
• Negative Sentiment: Northland Securities lowered several 2027 quarterly EPS estimates and cut its FY2027 forecast to $4.79 from $5.43. It maintained an Outperform rating and $315 target, while raising its FY2026 estimate to $2.99, making the revisions mixed overall.
• Negative Sentiment: Director Stefan Dyckerhoff disclosed stock sales under a pre-arranged Rule 10b5-1 plan. Such planned sales may add to concern about insider activity, though the trading plan makes them less indicative of a new view on the company.

Analysts Set New Price Targets

Several research firms have issued reports on ALAB. Northland Securities raised Astera Labs from a “market perform” rating to an “outperform” rating and set a $315.00 price target on the stock in a report on Wednesday, November 4th. Barclays lifted their target price on Astera Labs from $200.00 to $325.00 and gave the stock an “equal weight” rating in a report on Monday, July 20th. Weiss Ratings lowered Astera Labs from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, October 23rd. Jefferies Financial Group lifted their price target on Astera Labs from $270.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Citigroup downgraded Astera Labs from a “buy” rating to a “hold” rating in a report on Friday, October 9th. Thirteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $320.85.

Astera Labs Price Performance

The stock has a fifty day moving average price of $297.39 and a 200-day moving average price of $256.20. The company has a market cap of $37.78 billion, a PE ratio of 86.13 and a beta of 3.86.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.13. The business had revenue of $584.90 million for the quarter, compared to the consensus estimate of $550.78 million. Astera Labs had a return on equity of 25.35% and a net margin of 29.64%. Astera Labs’s revenue for the quarter was up 153.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.49 earnings per share. On average, equities analysts anticipate that Astera Labs, Inc. will post 2.99 earnings per share for the current year.

Insider Activity

In other news, COO Sanjay Gajendra sold 90,630 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $340.35, for a total value of $30,845,920.50. Following the transaction, the chief operating officer owned 1,119,038 shares in the company, valued at $380,864,583.30. This represents a 7.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stefan A. Dyckerhoff sold 8,994 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $211.41, for a total transaction of $1,901,421.54. Following the completion of the sale, the director directly owned 1,987 shares of the company’s stock, valued at $420,071.67. This trade represents a 81.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 408,558 shares of company stock worth $126,050,884. Corporate insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ALAB. Greenleaf Trust boosted its stake in shares of Astera Labs by 1.8% during the 2nd quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock valued at $966,000 after buying an additional 36 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Astera Labs by 74.5% in the second quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock worth $46,000 after acquiring an additional 41 shares during the last quarter. Integrated Advisors Network LLC raised its holdings in shares of Astera Labs by 4.8% during the third quarter. Integrated Advisors Network LLC now owns 983 shares of the company’s stock worth $350,000 after acquiring an additional 45 shares in the last quarter. Interchange Capital Partners LLC raised its holdings in shares of Astera Labs by 4.4% during the third quarter. Interchange Capital Partners LLC now owns 1,187 shares of the company’s stock worth $423,000 after acquiring an additional 50 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its holdings in shares of Astera Labs by 2.7% during the first quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock worth $209,000 after acquiring an additional 51 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

About Astera Labs

Astera Labs, Inc. is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help move data among processors, accelerators, memory and other components in high-performance computing systems. The company’s portfolio includes Aries PCIe and CXL retimers, Taurus Ethernet smart cable modules, Scorpio fabric switches and Leo CXL memory connectivity controllers. Astera Labs also offers software tools to help customers configure and monitor its connectivity products.